Laboratory Tests of Platelet Function

Total Page:16

File Type:pdf, Size:1020Kb

Laboratory Tests of Platelet Function A nnals of C linical Laboratory Science, Vol. 2, N o . 1 Copyright © 1972, Institute for Clinical Science Laboratory Tests of Platelet Function H. JAMES DAY, M.D. and HOLM HOLMSEN, Ph .D. Hematology Laboratories, Temple University School of Medicine Philadelphia, PA 19140 Introduction portant adenine nucleotide released is ADP, There has been growing interest in the a powerful platelet aggregating substance. role of platelets in the hemostatic process. Platelets also contribute a major source of Following injury to the blood vessel wall, phospholipids required for platelet coagula­ the platelets are exposed to some substance tion and this has been identified as platelet in the basement membrane, which may or factor 3 or platelet thromboplastic factor. may not be collagen, which leads to the This phospholipid is not normally available rapid formation of a platelet plug. The on the platelet surface and only becomes steps involved here are those of adhesion so when the platelets are altered or acti­ to the site of injury and exposed basement vated. Hardisty and Hutton1 have shown membrane, then aggregation of the plate­ that Kaolin makes this thromboplastic activ­ lets during which time the platelets un­ ity available and Spaet and Cintron24 have dergo a release reaction. Formation of a shown that connective tissue suspensions permeable platelet plug then occurs and are equally active. Platelets are also re­ finally, the subsequent development into a quired for clot retraction, the energy for hemostatic plug with the incorporation of which is derived from the breakdown of fibrin strands. It is important to note that platelet ATP to ADP. During this time, the time needed for the formation of a plate­ fibrin strands form which tend to radiate let plug correlates well with the bleeding between the clumps of platelets which act time measured from the beginning of the as the nidus of clot retraction. To date, clot infliction of the wound to the time the retraction has only been shown to be abnor­ bleeding ceases, i.e., approximately 6 min­ mal in those patients who have a defect utes. Thus, in performing a bleeding time, known as thrombasthenia and in those who the steps are measured which are necessary lack a normal number of platelets, i.e., for platelet plug formation. In vitro the thrombocytopenia. It is uncertain which function of platelets is tested by measuring role clot retraction plays in the mainte­ platelet adhesion to glass, aggregation with nance of normal hemostasis. various agents, the release reaction, clot re­ 5-Hydroxytryptamine (5-HT), a power­ traction, platelet-phagocytosis and platelet ful vasoconstrictor, is also carried by the uptake of numerous substances. platelets and released during the platelet Platelets contain large amounts of ade­ release reaction. The role of 5-HT in nor­ nine nucleotides which are released during mal hemostasis is not known, but recent the platelet release reaction, an important evidence has shown that a low platelet step in hemostasis. Possibly the most im­ serotonin level is often associated with low 63 64 DAY AND HOLMSEN releasable nucleotide levels. Thus, plate­ disease, etc. It is not in the scope of this lets are unable to release aggregating mate­ paper to discuss these in detail. More rials and hemorrhagic manifestations result. detailed general review papers on this Such a defective release reaction is typical subject should be consulted.12- ls- 16- 20 of thrombopathy or thrombocytopathy, a clinical condition characterized by hemor­ Methods rhagic manifestations. This paper will describe those tests of By definition, patients having defects in platelet function which are simple to per­ platelet function (also called qualitative form and yield the desired information. All platelet disorders) are those who have a are now available for use in clinical normal platelet count, but a prolonged laboratories. bleeding time owing to abnormal function­ ing platelets. It is generally accepted that Collection of Blood Sample bleeding phenomena do not occur unless the platelet count is below 2 0 ,0 0 0 per mm3. It is important to collect a sample of However, some patients, specifically those blood from a normal subject at the same with thrombopathy, may have platelet time as that of the patient if detailed tests counts that are in the range of 75 to 150,000 of platelet function are to be performed. per mm3 and have bleeding phenomena The volume of blood to be drawn for study even with this relatively minor thrombocy­ of platelet function may vary anywhere topenia. Under these circumstances, the from 9 to 38 ml. As performed in our platelets can often be shown to have a laboratory, 18 or 38 ml of blood are drawn functional defect. by gravity into plastic conical tubes by free The major diseases of platelet function flow into 2 ml or 4 ml of 0.11 M sodium that have been identified to date are classi­ citrate (31.3 g per 1 trisodium citrate 'H^O) fied in the following manner: with a teflon coated needle attached to a 1. Thrombasthenia — a disease which plastic tubing. The tube is then capped seems to be characterized by a defec­ with parafilm and inverted several times tive platelet membrane resulting in a for adequate mixing. Two blood smears failure of platelet aggregation. are also made at this time for staining with 2. Thrombopathy — in which there is a Wright’s stain and examined with particular failure of the release mechanism in reference to platelet number, platelet mor­ platelets and a failure to make plate­ phology and the presence or absence of let factor 3 (PF3) available. platelet aggregates. A sample of the whole 3. Von Willebrands disease or pseudo­ blood is then submitted for platelet count­ hemophilia—which is characterized by ing by standard electronic counting tech­ niques. Plastic equipment or siliconized a prolonged bleeding time and a low glassware is used for all platelet transfers. factor VIII. Strictly, this is not a platelet functional abnormality in as Preparation of Platelet-Rich and much as the platelets function per­ fectly well, but is included mainly Platelet-Poor Plasma because of a prolonged bleeding time. Citrated whole blood is centrifuged for These patients lack a plasma factor ten minutes at 2 0 0 x g at room temperature. called von Willebrand’s factor. It is important that the platelets not be Many platelet functional abnormalities subjected to extreme cold. The platelet-rich are seen as secondary to other disease plasma (PRP) is then transferred to a sec­ states. These include renal diseases, para- ond plastic tube, care being taken to avoid proteinemias, thrombocythemia, iatrogenic transferring any red cells. A platelet count LABORATORY TESTS OF PLATELET FUNCTION 65 is performed on this PRP which is kept Bleeding Time at room temperature until tested. Approxi­ Introduction mately 5 ml of PRP is re-centrifuged at 4°C for 30 minutes at 2,000 xg to remove The bleeding time is perhaps the best platelets and obtain platelet poor plasma screening test for defects of platelet func­ (PPP), which is collected and kept at 22 tion. As mentioned previously it measures to 25 °C until tested. the entire sequence of events in the forma­ tion of the hemostatic platelet plug. When Capillary Resistance the bleeding time is abnormal, other tests of platelet function are performed which Principle yield specific information as to the specific The test for capillary resistance, called type of hemostatic defect. the tourniquet test, is performed every time a venous blood specimen is obtained with Principle venostasis. It is best quantitated by putting A standard incision is made through the a blood pressure cuff on the arm and inflat­ skin and the time necessary for stopping of ing it to a point mid-way between systole bleeding is carefully measured. As useful and diastole (about 100 mm Hg). The as is this test, it must be rigidly controlled. cuff is left in place for 3 to 4 minutes with The method of Ivy et al. 13 is preferred in an area approximately the size of a half- as much as it is better controlled than any dollar, circumscribed on the volar aspect others. Recent modifications1’ 4- 17 have in­ of the forearm. The number of petechiae troduced even further methods for quanti­ in this area are then counted following tating the bleeding time. Strict attention deflation of the cuff. Some petechiae also must be paid to detail and each laboratory occur on the dorsum of the hand, this area must establish its normal range. should be observed closely. At the same time petechiae may develop in the area to Procedure1, 4 which the cuff is applied. A sphygnomanometer is placed around Discussion the patient’s arm and inflated to 40 mm of mercury. Following adequate cleansing of The test is not very useful in assessing the volar surface of the forearm, three platelet function because the results may parallel cuts are made on the forearm with be abnormal in many disease states, only a #11 Bard-Parker blade. These cuts some of which are related to abnormal should be 5 to 6 mm long, 1 mm deep and hemostatic processes . It is generally abnor­ 1.5 cm apart. Blood is carefully absorbed mal in thrombasthenia and von Wille- with the edge of a filter paper every 30 s brand’s disease, but more commonly it is until bleeding ceases, the wound itself not pathological in patients with severe throm­ being touched. Wounds which bleed pro­ bocytopenia or increased vascular fragility. fusely from the start probably represent Patients who develop petechiae under the perforated veins. Those which do not cuff or on the dorsum of the hand usually bleed for at least 2 minutes are assumed to have increased vascular fragility.
Recommended publications
  • Section 8: Hematology CHAPTER 47: ANEMIA
    Section 8: Hematology CHAPTER 47: ANEMIA Q.1. A 56-year-old man presents with symptoms of severe dyspnea on exertion and fatigue. His laboratory values are as follows: Hemoglobin 6.0 g/dL (normal: 12–15 g/dL) Hematocrit 18% (normal: 36%–46%) RBC count 2 million/L (normal: 4–5.2 million/L) Reticulocyte count 3% (normal: 0.5%–1.5%) Which of the following caused this man’s anemia? A. Decreased red cell production B. Increased red cell destruction C. Acute blood loss (hemorrhage) D. There is insufficient information to make a determination Answer: A. This man presents with anemia and an elevated reticulocyte count which seems to suggest a hemolytic process. His reticulocyte count, however, has not been corrected for the degree of anemia he displays. This can be done by calculating his corrected reticulocyte count ([3% × (18%/45%)] = 1.2%), which is less than 2 and thus suggestive of a hypoproliferative process (decreased red cell production). Q.2. A 25-year-old man with pancytopenia undergoes bone marrow aspiration and biopsy, which reveals profound hypocellularity and virtual absence of hematopoietic cells. Cytogenetic analysis of the bone marrow does not reveal any abnormalities. Despite red blood cell and platelet transfusions, his pancytopenia worsens. Histocompatibility testing of his only sister fails to reveal a match. What would be the most appropriate course of therapy? A. Antithymocyte globulin, cyclosporine, and prednisone B. Prednisone alone C. Supportive therapy with chronic blood and platelet transfusions only D. Methotrexate and prednisone E. Bone marrow transplant Answer: A. Although supportive care with transfusions is necessary for treating this patient with aplastic anemia, most cases are not self-limited.
    [Show full text]
  • Common Laboratory Values
    AmericAn AcAdemy of PediAtric dentistry Reference Manual 2006-2007 Resource Section 251 Common LaboratoryCommon Values Laboratory Values CBC Test Normal value Function Significance Hemoglobin 12-18 g/100 mL Measures oxygen carrying capacity of blood Low: hemorrhage, anemia High: polycythemia Hematocrit 35%-50% Measures relative volume of cells and plasma in Low: hemorrhage, anemia blood High: polycythemia, dehydration Red blood cell 4-6 million/mm3 Measures oxygen-carrying capacity of blood Low: hemorrhage, anemia High: polycythemia, heart disease, pulmonary disease White blood cell Measures host defense against inflammatory agents Low: aplastic anemia, drug toxicity, Infant 8,000-15,000/mm3 specific infections 4-7 y 6,000-15,000/mm3 High: inflammation, trauma, 8-18 y 4,500-13,500/mm3 toxicity, leukemia Differential Count Test Normal value Significance Neutrophils 54%-62% Increase in bacterial infections, hemorrhage, diabetic acidosis Lymphocytes 25%-30% Viral and bacterial infection, acute and chronic lymphocytic leukemia, antigen reaction Eosinophils 1%-3% Increase in parasitic and allergic conditions, blood dyscrasias, pernicious anemia Basophils 1% Increase in types of blood dyscrasias Monocytes 0%-9% Hodgkin’s disease, lipid storage disease, recovery from severe infections, monocytic leukemia Absolute Neutrophil Count (ANC) Calculation Normal value Significance (% Polymorphonuclear Leukocytes + % Bands)×Total White Cell Count >1500 <1000 Patient at increased risk for 100 infection; defer elective dental care Bleeding Screen Test
    [Show full text]
  • Prolonged Partial Thromboplastin Time Without Bleeding History; Fletcher Factor Deficiency
    Prolonged Partial Thromboplastin Time Without Bleeding History; Fletcher Factor Deficiency Celalettin ÜSTÜN*, Anand JILLELLA*, Linda HENDRIKS*, Mary JONAH**, Ferdane KUTLAR*, Russell BURGESS*, Abdullah KUTLAR* * Section of Hematology Oncology, Department of Medicine, Medical College of Georgia, ** Department of Pathology, Medical College of Georgia, Augusta, USA ABSTRACT A 67-year-old patient was admitted to the hospital to perform an esophagogastrectomy because a lesion at the lower esophagus was strongly suspicious for cancer. Her medical history and her family his- tory were negative for bleeding tendency or thrombosis. Her activated partial thromboplastin time (aPTT) was prolonged (44 s) whereas her prothrombin time (PT) was normal (11 s) presurgery. Mixing of her plasma with normal plasma corrected her prolonged aPTT (27.9 s). Prolonged incubation shortened the patient’s aPTT (36.3 s). Fletcher factor activity was found to be 50%. The patient underwent an esopha- gogastrectomy without bleeding complications under spinal anesthesia. Fletcher factor deficiency, a ra- re disorder, should be considered in patients who have no history of bleeding tendency with a prolonged aPTT. Surgical interventions are safe in these patients. Key Words: aPTT, Surgery, Fletcher factor, Prekallikrein. Turk J Haematol 2002;19(3): 417-419 Received: 20.06.2001 Accepted: 28.07.2001 INTRODUCTION unt[2]. Hematologists are frequently consulted for preoperative coagulation abnormalities. Preoperative evaluation of hemostasis is cru- cial to assess the risk of per-and peri-operative Prolonged aPTT is not an uncommon abnor- bleeding. The most effective screening method is mality encountered during preoperative evaluati- to obtain a thorough history of bleeding[1]. on. It may indicate the presence of antiphospholi- Preoperative screening tests mostly include acti- pid antibodies or a factor deficiency in the intrinsic vated partial thromboplastin time (aPTT), proth- and/or common pathways of blood coagulation.
    [Show full text]
  • Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma: a Single-Centre, Observer-Blinded, Randomized Controlled Trial (Trace)
    TRANEXAMIC ACID IN THE TREATMENT OF RESIDUAL CHRONIC SUBDURAL HEMATOMA: A SINGLE-CENTRE, OBSERVER-BLINDED, RANDOMIZED CONTROLLED TRIAL (TRACE) by Adriana Micheline Workewych A thesis submitted in conformity with the requirements for the degree of Master of Science Institute of Medical Science University of Toronto © Copyright by Adriana Micheline Workewych 2018 TRANEXAMIC ACID IN THE TREATMENT OF RESIDUAL CHRONIC SUBDURAL HEMATOMA: A SINGLE-CENTRE, OBSERVER-BLINDED, RANDOMIZED CONTROLLED TRIAL (TRACE) Adriana Micheline Workewych Master of Science Institute of Medical Science University of Toronto 2018 ABSTRACT Chronic subdural hematoma (CSDH) is a frequent consequence of head trauma, particularly in older individuals. Given the aging of populations globally, its incidence is projected to increase substantially. Hyperfibrinolysis may be central to CSDH enlargement by causing excessive clot degradation and liquefaction, impeding resorption. The only current standard treatment for CSDH is surgery, however, up to 31% of residual hematomas enlarge, requiring reoperation. Tranexamic acid (TXA), an antifibrinolytic medication that prevents excessively rapid clot breakdown, may help prevent CSDH enlargement, potentially eliminating the need for repeat surgery. To evaluate the feasibility of conducting a trial investigating TXA efficacy in residual CSDH, we conducted an observer-blinded, pilot randomized controlled trial (RCT). We showed this trial was feasible and safe, reporting only minor to moderate AEs, and an attrition rate of 4%. The results from this study will inform the conduct of a double-blinded RCT investigating TXA efficacy in post-operative CSDH management. ii ACKNOWLEDGEMENTS First, I would like to thank my supervisor Dr. Michael Cusimano, my mentor for nearly six years. You have always given me more opportunity than I could have ever hoped for – I could not ask for a more dedicated teacher.
    [Show full text]
  • Path Ggf 5 2020.Pdf
    Hemostasis Hemostasis and Thrombosis Normal hemostasis is a consequence of tightly regulated processes that maintain blood in a fluid state in normal vessels, yet also permit the rapid formation of a hemostatic clot at the site of a vascular injury. Thrombosis involves blood clot formation within intact vessels. Both hemostasis and thrombosis involve three components: the vascular wall, platelets and the coagulation cascade. Elements of the Hemostatic process • Endothelium • Anti-thrombosis • Pro-thrombosis • Platelets • Platelet-endothelial cell interaction • Coagulation cascade http://www.as.miami.edu/chemistry/2086/chapter_21/NEW-Chap21_class_part1_files/image002.jpg After initial injury there is a brief period of arteriolar vasoconstriction mediated by reflex neurogenic mechanisms and augmented by the local secretion of factors such as endothelin (a potent endothelium-derived vasoconstrictor) The effect is transient, however, and bleeding would resume if not for activation of the platelet and coagulation systems. Endothelial injury exposes highly thrombogenic subendothelial extracellular matrix (ECM), facilitating platelet adherence and activation. Activation of platelets results in a dramatic shape change (from small rounded discs to flat plates with markedly increased surface area), as well as the release of secretory granules. Within minutes the secreted products recruit additional platelets (aggregation) to form a hemostatic plug; this process is referred to as primary hemostasis. http://www.ouhsc.edu/platelets/Platelet%20Pic s/Platelets3.jpg http://medcell.med.yale.edu/histology/blood_bone_marr ow_lab/images/platelets_em.jpg Tissue factor is also exposed at the site of injury. Also known as factor III and thromboplastin, tissue factor is a membrane-bound procoagulant glycoprotein synthesized by endothelial cells. It acts in conjunction with factor VII (see below) as the major in vivo initiator of the coagulation cascade, eventually culminating in thrombin generation.
    [Show full text]
  • The Minimum Concentration of Fibrinogen Needed for Platelet Aggregation Using ADP
    RESEARCH ○○○○○○○○ The Minimum Concentration of Fibrinogen Needed for Platelet Aggregation using ADP ROBERT F CORNELL, TIM R RANDOLPH ○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○ OBJECTIVE: Determine the minimum concentration of plasma INDEX TERMS: ADP; aggregation; fibrinogen; platelets. fibrinogen needed to stimulate the aggregation of platelets, col- lected from normal subjects, using ADP. Clin Lab Sci 2001;15(1):30 DESIGN: Platelet rich plasmas (300 x 109 platelets/L) were made Robert F Cornell II was a student in the Department of Clinical and adjusted to final fibrinogen concentrations of 75, 19, 5, and 0 Laboratory Science, Saint Louis University Health Sciences Center, St mg/dL using fibrinogen free serum. Each fibrinogen concentra- Louis MO when this research was done. Downloaded from tion in all twelve subjects was aggregated with ADP. Tim R Randolph MS is an Assistant Professor in the Department of SETTING: Research laboratory in the Department of Clinical Clinical Laboratory Science, School of Allied Health Professions, Saint Laboratory Science at Saint Louis University. Louis University Health Sciences Center, St Louis MO. PARTICIPANTS: Twelve healthy volunteers of both genders, be- Address for correspondence: Tim R Randolph MS, Saint Louis Uni- http://hwmaint.clsjournal.ascls.org/ tween the ages of 18 and 60 years who were not pregnant and versity School of Allied Health Professions, Department of Clinical Labo- weighed at least 110 pounds were included in the study. Subjects ratory Science, Room 3096, 3437 Caroline St, St Louis MO 63104. were excluded from the study if they had ingested aspirin within (314) 577-8518, (314) 577-8503 (fax). [email protected] one week prior to blood collection.
    [Show full text]
  • Biomechanical Thrombosis: the Dark Side of Force and Dawn of Mechano-­ Medicine
    Open access Review Stroke Vasc Neurol: first published as 10.1136/svn-2019-000302 on 15 December 2019. Downloaded from Biomechanical thrombosis: the dark side of force and dawn of mechano- medicine Yunfeng Chen ,1 Lining Arnold Ju 2 To cite: Chen Y, Ju LA. ABSTRACT P2Y12 receptor antagonists (clopidogrel, pras- Biomechanical thrombosis: the Arterial thrombosis is in part contributed by excessive ugrel, ticagrelor), inhibitors of thromboxane dark side of force and dawn platelet aggregation, which can lead to blood clotting and A2 (TxA2) generation (aspirin, triflusal) or of mechano- medicine. Stroke subsequent heart attack and stroke. Platelets are sensitive & Vascular Neurology 2019;0. protease- activated receptor 1 (PAR1) antag- to the haemodynamic environment. Rapid haemodynamcis 1 doi:10.1136/svn-2019-000302 onists (vorapaxar). Increasing the dose of and disturbed blood flow, which occur in vessels with these agents, especially aspirin and clopi- growing thrombi and atherosclerotic plaques or is caused YC and LAJ contributed equally. dogrel, has been employed to dampen the by medical device implantation and intervention, promotes Received 12 November 2019 platelet thrombotic functions. However, this platelet aggregation and thrombus formation. In such 4 Accepted 14 November 2019 situations, conventional antiplatelet drugs often have also increases the risk of excessive bleeding. suboptimal efficacy and a serious side effect of excessive It has long been recognized that arterial bleeding. Investigating the mechanisms of platelet thrombosis
    [Show full text]
  • BLOOD COAGULATION TESTS 17 Lea E
    HEMATOLOGY: BLOOD COAGULATION TESTS 17 Lea E. Dela Peña Normal hemostasis involves a complex interaction among the vascular subendothe- OBJECTIVES lium, platelets, coagulation factors, and proteins that promote clot formation, clot degradation and inhibitors of these substances. Disruption in normal hemostasis can After completing this chapter, the result in bleeding or excessive clotting. Bleeding can be caused by trauma or damage reader should be able to to vessels, acquired or inherited deficiencies of coagulation factors, or physiological • Describe the role of platelets, disorders of platelets, whereas excessive clotting can result from abnormalities of the the coagulation cascade, and vascular endothelium, alterations in blood flow, or deficiencies in clotting inhibitors. fibrinolytic system in normal Clinicians must monitor the hemostasis process in individual patients to ensure hemostasis their safety from an imbalance in this complex system. For example, practitioners routinely order platelet tests in patients on certain antineoplastic medications to • List the laboratory tests used assess for thrombocytopenia. Likewise, clinicians closely monitor coagulation tests to assess platelets and discuss for patients receiving anticoagulants to prevent thromboembolic or hemorrhagic factors that may influence their complications. Overall, the hemostatic process is intricate and requires a clinician results knowledgeable in its dynamics for quality assessment. • List the laboratory tests used This chapter reviews normal coagulation physiology,
    [Show full text]
  • The Preoperative Bleeding Time Test: Assessing Its Clinical Usefulness
    The preoperative bleeding time test: assessing its clinical usefulness AMY S. GEWIRTZ, MD; KANDICE KOTTKE-MARCHANT MD, PHD; MICHAEL L. MILLER, DO HE BLEEDING TIME is the The bleeding time test can aid in the diagnostic most commonly used evaluation of patients with clinical hemorrhagic disorders or test in the in vivo evalu- a history of bleeding. However, its low positive predictive ation of primary hemo- value in predicting perioperative bleeding should force one to T stasis. Although this test is known abandon it as a routine preoperative screening test. for its role in the evaluation of pa- tients suspected of having von INa'iiV Ji J Many methodologic factors affect the bleeding Willebrand's disease or abnormal time, including the length, depth, orientation, and location platelet function, it is quite often of the incision and whether a blood pressure cuff is used. The routinely ordered as part of preop- bleeding time also varies with age, sex, blood group, medica- erative screening to predict periop- tion use, skin characteristics, and diet. A prolonged bleed- erative bleeding in patients with ing time itself is nonspecific and is not pathognomonic of a no previous clinical signs of a single disease entity. Many studies have shown no associa- bleeding disorder. Physicians tion between a prolonged preoperative bleeding time and in- should be familiar with factors that creased perioperative blood loss. Even though a prolonged affect the standardization, reliabil- preoperative bleeding time usually lacks clinical significance, ity and specificity of the bleeding it often leads to additional laboratory tests, postponement of time test, as well as the pitfalls of surgery, increased length of stay, and possibly inappropriate using it to predict clinically signifi- treatment.
    [Show full text]
  • The Molecular Basis of Blood Coagulation Review
    Cell, Vol. 53, 505-518, May 20, 1988, Copyright 0 1988 by Cell Press The Molecular Basis Review of Blood Coagulation Bruce Furie and Barbara C. Furie into the fibrin polymer. The clot, formed after tissue injury, Center for Hemostasis and Thrombosis Research is composed of activated platelets and fibrin. The clot Division of Hematology/Oncology mechanically impedes the flow of blood from the injured Departments of Medicine and Biochemistry vessel and minimizes blood loss from the wound. Once a New England Medical Center stable clot has formed, wound healing ensues. The clot is and Tufts University School of Medicine gradually dissolved by enzymes of the fibrinolytic system. Boston, Massachusetts 02111 Blood coagulation may be initiated through either the in- trinsic pathway, where all of the protein components are present in blood, or the extrinsic pathway, where the cell- Overview membrane protein tissue factor plays a critical role. Initia- tion of the intrinsic pathway of blood coagulation involves Blood coagulation is a host defense system that assists in the activation of factor XII to factor Xlla (see Figure lA), maintaining the integrity of the closed, high-pressure a reaction that is promoted by certain surfaces such as mammalian circulatory system after blood vessel injury. glass or collagen. Although kallikrein is capable of factor After initiation of clotting, the sequential activation of cer- XII activation, the particular protease involved in factor XII tain plasma proenzymes to their enzyme forms proceeds activation physiologically is unknown. The collagen that through either the intrinsic or extrinsic pathway of blood becomes exposed in the subendothelium after vessel coagulation (Figure 1A) (Davie and Fiatnoff, 1964; Mac- damage may provide the negatively charged surface re- Farlane, 1964).
    [Show full text]
  • Circular of Information for the Use of Human Blood and Blood Components
    CIRCULAR OF INFORMATION FOR THE USE OF HUMAN BLOOD Y AND BLOOD COMPONENTS This Circular was prepared jointly by AABB, the AmericanP Red Cross, America’s Blood Centers, and the Armed Ser- vices Blood Program. The Food and Drug Administration recognizes this Circular of Information as an acceptable extension of container labels. CO OT N O Federal Law prohibits dispensing the blood and blood compo- nents describedD in this circular without a prescription. THIS DOCUMENT IS POSTED AT THE REQUEST OF FDA TO PROVIDE A PUBLIC RECORD OF THE CONTENT IN THE OCTOBER 2017 CIRCULAR OF INFORMATION. THIS DOCUMENT IS INTENDED AS A REFERENCE AND PROVIDES: Y • GENERAL INFORMATION ON WHOLE BLOOD AND BLOOD COMPONENTS • INSTRUCTIONS FOR USE • SIDE EFFECTS AND HAZARDS P THIS DOCUMENT DOES NOT SERVE AS AN EXTENSION OF LABELING REQUIRED BY FDA REGUALTIONS AT 21 CFR 606.122. REFER TO THE CIRCULAR OF INFORMATIONO WEB- PAGE AND THE DECEMBER 2O17 FDA GUIDANCE FOR IMPORTANT INFORMATION ON THE CIRCULAR. C T O N O D Table of Contents Notice to All Users . 1 General Information for Whole Blood and All Blood Components . 1 Donors . 1 Y Testing of Donor Blood . 2 Blood and Component Labeling . 3 Instructions for Use . 4 Side Effects and Hazards for Whole Blood and P All Blood Components . 5 Immunologic Complications, Immediate. 5 Immunologic Complications, Delayed. 7 Nonimmunologic Complications . 8 Fatal Transfusion Reactions. O. 11 Red Blood Cell Components . 11 Overview . 11 Components Available . 19 Plasma Components . 23 Overview . 23 Fresh Frozen Plasma . .C . 23 Plasma Frozen Within 24 Hours After Phlebotomy . 28 Components Available .
    [Show full text]
  • Topic: Bleeding 2015
    Department of General Surgery Medical Academy named after S.I. Georgievskiy, The Federal State Autonomous Educational Establishment of Higher Education “Crimean Federal University named after V.I. Vernadsky” Ministry of Education and Science of the Russian Federation For the 3rd year students The text of the lectures and the minimum amount of knowledge necessary for a understanding of the subject material. Topic: Bleeding Authors: prof.Mikhailychenko V.Yu, Starykh A.A. 2015 Bleeding Bleeding, technically known as hemorrhaging or hæmorrhaging (see American and British spelling differences), is blood escaping from the circulatory system. Etiology : trauma and some diseases (tuberculosis, cancer, peptic ulcer). What is blood? Functions of blood. Blood is basically a type of a connective tissue which is found in the human body in fluid state. It is made up of plasma which is a highly viscous liquid and 3 different types of blood cells that are floating around in it. Almost 92% of the plasma is water while the rest consists of enzymes, hormones, antibodies, nutrients, gases, salts, proteins and metabolites of various kinds. Besides plasma, the cellular constituents of blood are red and white blood cells and platelets. What are the functions of blood? What about the functions for each blood component? Functions of Blood Blood performs many important functions within the body including: Supply of oxygen to tissues (bound to hemoglobin, which is carried in red cells) Supply of nutrients such as glucose, amino acids, and fatty acids (dissolved in the blood or bound to plasma proteins (e.g., blood lipids)) Removal of waste such as carbon dioxide, urea, and lactic acid Immunological functions, including circulation of white blood cells, and detection of foreign material by antibodies Coagulation, the response to a broken blood vessel, the conversion of blood from a liquid to a semi-solid gel to stop bleeding.
    [Show full text]